Scotiabank Comments on Albemarle’s Q1 Earnings (NYSE:ALB)

Albemarle Co. (NYSE:ALB) – Equities research analysts at Scotiabank issued their Q1 2025 earnings estimates for Albemarle in a research note issued to investors on Tuesday, February 18th. Scotiabank analyst B. Isaacson expects that the specialty chemicals company will post earnings of ($0.14) per share for the quarter. Scotiabank currently has a “Sector Perform” rating and a $75.00 target price on the stock. The consensus estimate for Albemarle’s current full-year earnings is $1.44 per share. Scotiabank also issued estimates for Albemarle’s FY2026 earnings at $2.51 EPS.

Albemarle (NYSE:ALB) last issued its quarterly earnings results on Wednesday, February 12th. The specialty chemicals company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.49). Albemarle had a negative return on equity of 1.72% and a negative net margin of 21.93%.

ALB has been the topic of a number of other reports. Morgan Stanley dropped their price target on shares of Albemarle from $73.00 to $68.00 and set an “underweight” rating on the stock in a research note on Tuesday. Evercore ISI downgraded shares of Albemarle from an “outperform” rating to an “inline” rating in a report on Wednesday, February 5th. Oppenheimer decreased their price objective on shares of Albemarle from $171.00 to $170.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. Clarkson Capital started coverage on shares of Albemarle in a report on Tuesday, January 14th. They set a “buy” rating and a $112.00 price objective on the stock. Finally, KeyCorp decreased their price objective on shares of Albemarle from $127.00 to $122.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Albemarle has a consensus rating of “Hold” and a consensus target price of $109.91.

Albemarle Trading Down 0.0 %

Shares of Albemarle stock opened at $83.55 on Thursday. Albemarle has a 52-week low of $71.97 and a 52-week high of $143.19. The company has a quick ratio of 1.19, a current ratio of 1.95 and a debt-to-equity ratio of 0.39. The company’s 50-day simple moving average is $87.71 and its 200-day simple moving average is $92.14. The firm has a market cap of $9.82 billion, a price-to-earnings ratio of -7.46, a price-to-earnings-growth ratio of 3.52 and a beta of 1.59.

Insider Activity at Albemarle

In related news, CEO J Kent Masters sold 2,525 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $101.12, for a total transaction of $255,328.00. Following the transaction, the chief executive officer now owns 73,747 shares of the company’s stock, valued at approximately $7,457,296.64. This represents a 3.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.38% of the company’s stock.

Hedge Funds Weigh In On Albemarle

Several institutional investors and hedge funds have recently modified their holdings of ALB. Quarry LP increased its position in Albemarle by 1,400.0% during the third quarter. Quarry LP now owns 270 shares of the specialty chemicals company’s stock worth $26,000 after purchasing an additional 252 shares during the last quarter. Assetmark Inc. increased its position in Albemarle by 340.6% during the fourth quarter. Assetmark Inc. now owns 304 shares of the specialty chemicals company’s stock worth $26,000 after purchasing an additional 235 shares during the last quarter. Trust Co. of Vermont increased its position in Albemarle by 606.5% during the fourth quarter. Trust Co. of Vermont now owns 325 shares of the specialty chemicals company’s stock worth $28,000 after purchasing an additional 279 shares during the last quarter. Eastern Bank acquired a new position in Albemarle during the third quarter worth approximately $31,000. Finally, Cromwell Holdings LLC increased its position in Albemarle by 61.9% during the third quarter. Cromwell Holdings LLC now owns 387 shares of the specialty chemicals company’s stock worth $37,000 after purchasing an additional 148 shares during the last quarter. Hedge funds and other institutional investors own 92.87% of the company’s stock.

About Albemarle

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.